This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Malik, S. N. Articles by Kreisberg, J. I. Search for Related Content PubMed PubMed Citation Articles by Malik, S. N. Articles by Kreisberg, J. I.

Immunohistochemical Demonstration of Phospho-Akt in High Gleason Grade Prostate Cancer¹

Departments of Surgery [S. N. M., P. M. G., R. B., J. I. K.] and Pathology [D. A. T., T. P.], University of Texas Health Science Center, San Antonio, Texas 78229; Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263 [M. B.]; and South Texas Veterans Health Care System, Audie Murphy Veterans Administration Hospital, San Antonio, Texas 78229 [J. I. K.]

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Purpose: Whereas the early stage of prostate cancer is marked by excessive proliferation, in advanced stages of the disease, a decreased apoptotic death rate (increased cell survival) also contributes to net tumor growth. Altered regulation of the mitogen-activated protein kinase (MAPK)-regulated cell proliferation and Akt-regulated cell survival pathways are suspected causes. In this study, we wanted to determine: (a) whether the degree of Akt activation can be assessed by immunohistochemical staining of paraffin- embedded human prostate cancer biopsies with an antibody to phospho-Akt (Ser473); and (b) whether phospho-MAPK/Erk1/2 and phospho-Akt expression are altered in prostate cancer.

Experimental design: To examine the activation status of MAPK/Erk1/2 and Akt, archival paraffin-embedded sections from 74 cases of resected prostate cancer were immunostained with antibodies to phospho-MAPK/Erk1/2 (Thr202/ Tyr204) and phospho-Akt (Ser473).

Results: The staining intensity for phospho-Akt was significantly greater in Gleason grades 8–10 (92% of such cases staining strongly) compared with prostatic intraepithelial neoplasia and all other grades of prostate cancer (only 10% of these cases staining strongly; P 0.001). The staining intensity for phospho-MAPK/Erk, on the other hand, was significantly greater for normal, hyperplastic, and prostatic intraepithelial neoplasia lesions but declined with disease progression, reaching its lowest level of expression in high Gleason grades 8–10 (P < 0.0001).

Conclusion: The activation state of the cell survival protein Akt can be analyzed in human prostate cancer by immunohistochemical staining of paraffin-embedded tissue with a phospho-specific Akt (Ser473) antibody. Advanced disease is accompanied by activation of Akt and inactivation of Erk.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Prostate cancer causes more than 41,000 deaths annually in the United States and is the second leading cause of cancer deaths in men (1) . Although prostate cancer is initially dependent on androgens for growth and, thus, is responsive to androgen ablation, progression to an androgen-insensitive state generally ensues (1) . When this occurs, the prognosis is poor, because no systemic therapy is effective. Therefore, there is an urgent need for targeted nonhormonal treatment that inhibits prostatic cancer cells. In normal prostate epithelium, cell proliferation is balanced by an equal rate of apoptosis, such that there is neither involution nor overgrowth (1) . In prostate cancer this balance is altered. Whereas the early stage of the disease is marked by excessive proliferation, in advanced stages of the disease, net growth of the tumor results from a decreased apoptotic death rate (cell survival) in addition to increased proliferation (1) .

Activation of the PI3k³ /serine-threonine kinase Akt signaling pathway promotes cell survival by inhibiting apoptosis through phosphorylation of the proapoptotic protein BAD and other proteins (2, 3, 4, 5) , whereas activation of the MAPK signaling pathway is accompanied by increased cellular proliferation (6 , 7) . PTEN is a tumor suppressor gene that is altered and inactive in many types of tumors, including prostate cancer (2 , 3) . Among its substrates are the lipid products of PI3k, phosphatidylinositol 3,4,-bisphosphate, and phosphatidylinositol 3,4,5-trisphosphate, which mediate the activation of Akt (4 , 5) . It was demonstrated recently by IHC that high Gleason-grade prostate cancer displays loss of tumor suppressor phosphatase PTEN (2) . This suggests that increased activation of Akt in poorly differentiated prostatic carcinoma results from the loss of PTEN.

In this paper, with phospho-specific antibodies we demonstrate by IHC that advanced prostate cancer is accompanied by the expression of the activated (phosphorylated) form of Akt and decreased expression of activated MAPK/Erk1/2. These results may provide the molecular basis for the observed activation of a cell survival pathway that has been reported to contribute significantly to the progression of prostate cancer growth (1) .

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Primary Antibodies.
Rabbit polyclonal phospho-Akt (Ser 473; Cell Signaling Technology, Beverly, MA, Cat. No. 9277, IHC specific) was used at a 1:50 dilution; rabbit polyclonal phospho-p44/42 MAP kinase (Thr 202/Tyr 204; Cell Signaling Technology; IHC-specific) at a 1:50 dilution; rabbit polyclonal Akt (Santa Cruz Biotechnology Inc., Santa Cruz, CA) at a 1:50 dilution; and rabbit polyclonal Erk1 (Santa Cruz Biotechnology) at a 1:100 dilution.

Analysis of Human Tissues.
A total of 74 formalin-fixed, paraffin-embedded human primary prostate cancer specimens were studied from the archival files of Audie Murphy Veterans Medical Center. Fifty-three samples were obtained from radical prostatectomies, and 22 samples were obtained from transurethral resections. H&E-stained slides were reviewed for Gleason score. In a majority of the cases, adjacent areas of normal prostatic epithelium, benign prostatic hyperplasia, and PIN were also available for review along with infiltrating carcinoma.

IHC.
Sections were heated to 60°C, and rehydrated in xylene and graded alcohols. Antigen retrieval was performed with 0.01 M citrate buffer at pH 6.0 for 20 min in a 95% water bath. Slides were allowed to cool for another 20 min, followed by sequential rinsing in PBS and 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, Tween 20 (0.1%; TBS-T). Endogenous peroxidase activity was quenched by incubation in TBS-T containing 3% hydrogen peroxide. Each incubation step was carried out at room temperature and was followed by three sequential washes (5 min each) in TBS-T. Sections were incubated in primary antibody diluted in TBS-T containing 1% ovalbumin and 1 mg/ml sodium azide (12 h) followed by incubations with biotinylated secondary antibody for 15 min, peroxidase-labeled streptavidin for 15 min (LSAB-2; Dako Corp., Carpinteria, CA), and diaminobenzidine and hydrogen peroxide chromogen substrate (Dako Corp.) along with 3,3'-diaminobenzidine enhancer (Signet) for 10 min. Slides were counterstained with hematoxylin and mounted. The negative controls were incubated with nonimmune rabbit IgG in place of primary antibody.

One representative slide per case was evaluated with the above antibodies. The proportion of carcinoma and PIN staining, and the intensity of staining seen in different areas of the same slide were analyzed according to criteria described previously in the literature (8) . The intensity is designated as 0 when no tumor cells stain, 1+ when 10–20% of cells stain (weak), 2+ when 20–50% of cells stain (moderate), and 3+ when >50% of cells stain (strong).

Imaging.
Digital images for photomicroscopy were acquired with a Cool Snap camera from Nikon. Minor adjustments in the captured images were performed identically and in parallel for the images presented using Adobe PhotoShop 5.5. Composite images were made using Microsoft PowerPoint and printed on a Phaser 780 plus printer (Tetronix Co., Westborough, MA).

Statistics.
For statistical analyses, groups scored 0 and 1+ were combined ("weak staining") as were groups scored 2+ and 3+ ("strong staining"). Statistical analysis was performed by using ² analyses with Kappa and McNemar statistics in contingency tables for agreement and disagreement of specific comparisons (9) . Normality of residuals was assessed for phospho-Akt and phospho-MAPK Erk levels each analyzed separately to assure valid analyses. The analyses were performed using a statistical analysis system on a PC-compatible computer with SAS 6.12 software (SAS Institute, Cary, NC).

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Increased Expression of Phospho-Akt (Ser473) in Paraffin-embedded Poorly Differentiated Prostate Cancer.
The PI3k dependent serine threonine kinase Akt (also known as protein kinase B) has been implicated in mediating cell survival in various prostate cancer cells (2 , 3 , 10 , 11) . Therefore, we examined human prostate cancer tissues by IHC to determine whether the expression of the activated (phosphorylated) form of the cell survival protein Akt correlated with prostate cancer differentiation. Ninety percent of PIN, well to moderately differentiated adenocarcinomas, and Gleason score 7 carcinomas were either completely negative or showed only weak staining (intensity score of 0 to 1+) for phospho-Akt (P < 0.001; Fig. 1 ; Table 1 ). Phospho-Akt staining intensity progressed as the disease progressed with strongest staining observed in the highest Gleason scores. That is, >90% of poorly differentiated adenocarcinomas (Gleason score 8–10) exhibited strong staining for phospho-Akt (intensity score of 2 to 3+), (P 0.001; Fig. 1 ; Table 1 ). Interestingly, the staining appeared to be localized to the membrane where Akt has been shown to be active (4 , 5) . Total Akt levels were expressed in all of the tissues with no change in the degree of expression during disease progression.

View larger version (122K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Immunoperoxidase staining for phospho-Akt using a phospho-specific Akt (Ser 473) antibody. A, negative control. B, PIN showing weak cytoplasmic staining for phospho-Akt. C, well-differentiated adenocarcinoma showing weak cytoplasmic staining. D, poorly differentiated carcinoma showing strong membrane staining for phospho-Akt (x40, original magnification).

View larger version (137K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. Immunoperoxidase staining for phospho-Erk1/2 using a phospho-specific MAPK/Erk1/2 (Thr202/Tyr204) antibody. A, negative control. B, hyperplasia showing strong nuclear staining for phospho-MAPK/Erk1/2. C, PIN showing strong nuclear staining for phospho-MAPK/Erk1/2. D, poorly differentiated carcinoma showing weak staining for phospho-MAPK/Erk1/2. Note positive staining in vessels-serves as intrinsic positive control (x40, original magnification).

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

This is the first report of the immunohistochemical detection of phospho-(active) Akt using a phospho-specific antibody in paraffin-embedded human prostate cancer. Similar to our observations, Paweletz et al. (11) showed by reverse-phase protein microarrays that cancer progression was associated with increased phosphorylation of Akt and suppression of apoptotic pathways as measured using antibodies to cleaved caspase 7 and poly(ADP-ribose) polymerase.

Advanced prostate cancer is often accompanied by androgen independence, and growth of the tumor becomes dependent on activation of cell survival pathways as well as cell proliferation pathways. Graff et al. (10) showed that Akt activation was markedly increased in an androgen-independent LNCaP cell line that was isolated from LNCaP xenografts. In addition to increased Akt activation, there was increased phosphorylation and inactivation of the proapoptotic protein BAD, a target protein of Akt, and decreased expression of the cyclin inhibitor, p27kip1 (10) . These results would explain the emergence of an antiapoptotic pathway in androgen-independent prostate cancer as well as explain the enhanced proliferation observed in advanced prostate cancers. In human prostate cancer, the tumor suppressor phosphatase PTEN is mutated and inactive (2 , 3 , 10 , 11) . This phosphatase normally negatively regulates components of the PI3k pathway such as the cell survival protein Akt. Loss of PTEN activity is accompanied by increased expression of the activated form of Akt and activation of cell survival pathways. Similar to our findings by IHC, Paweletz et al. (11) demonstrated in protein microarrays that prostate tumor progression is accompanied by increased expression of phospho-Akt. Importantly, this coincided with suppression of apoptosis. Also similar to our findings, they showed that expression of phospho-Erk was suppressed with progression of disease. These findings are in contrast to the IHC studies by Gioeli et al. (12) who showed increased expression of phospho-MAPK with increasing Gleason score. Studies by Zimmerman and Moeling (13) may explain our observations of high phospho-Akt expression accompanied by low levels of phospho-MAPK/Erk; namely, they showed that phospho-Akt inactivates Raf by direct phosphorylation on Ser259, resulting in inhibition of the Raf-MEK-Erk signaling pathway. In conclusion, we show by IHC on paraffin-embedded tissue that progression of prostate cancer is accompanied by increased levels of phospho-Akt and decreased levels of phospho-MAPK/Erk. Understanding the mechanisms of prostate tumor growth could prove critical to developing new effective therapies for prostate cancer.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by a Merit Review from the Office of Research and Development, Medical Research Service, Department of Veterans Affairs (to J. I. K.), and a grant from the San Antonio Cancer Institute. J. I. K. is a Career Scientist with the Department of Veterans Affairs.

² To whom requests for reprints should be addressed, at Department of Surgery, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229. Phone: (210) 567-5892; Fax: (210) 567-4664; E-mail: kreisberg{at}uthscsa.edu

³ The abbreviations used are: PI3k, phosphatidylinositol 3'-kinase; MAPK, mitogen-activated protein kinase; IHC, immunohistochemistry; PIN, prostatic intraepithelial neoplasia; Erk, extracellular-regulated kinase; TBS-T, tris-buffered saline-tween.

Received 4/20/01; revised 1/17/02; accepted 1/28/02.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Denmeade S. R., Xiaohui S. L., Isaacs J. T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28: 251-265, 1996.[CrossRef][Medline]
2. McMenamin M. E., Soung P., Perera S., Kaplan I., Loda M., Sellers R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res., 59: 4291-4296, 1999.[Abstract/Free Full Text]
3. Persad S., Attwell S., Gray V., Delcommenne M., Troussard A., Sanghera J., Dedhar S. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN mutant prostate cancer cells. Proc Natl Acad. Sci. USA, 97: 3207-3212, 2000.[Abstract/Free Full Text]
4. Kandel E. S., Hay N. The regulation and activities of the multifunctional serine/threonine kinase AKT/PKB. Exp. Cell Res., 253: 210-229, 1999.[CrossRef][Medline]
5. Burgering B. M. T., Coffer P. Protein kinase B (c-Akt) in phosphatidylinositol 3-OH kinase signal transduction. Nature (Lond.), 376: 599-602, 1995.[CrossRef][Medline]
6. Lowenstein E. J., Daly R. J., Batzer A. G., Li W., Margolis B., Lammers R., Ullrich A., Skolnik E. Y., Bar-Sagi D. The SH2 and SH3 domains containing proteins GRB2 links receptor tyrosine kinases to ras signaling. Cell, 70: 431-442, 1992.[CrossRef][Medline]
7. Halberg B., Rayter S. I., Downward J. Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J. Biol. Chem., 269: 3913-3916, 1994.[Abstract/Free Full Text]
8. Allred D. C., Clark F. M., Elledge R., Fuqua S. A. W., Brown R. W., Chamness G. C., Osborne A. K., McGuire W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node negative breast cancer. J. Nat. Cancer Inst., 85: 200-206, 1993.[Abstract/Free Full Text]
9. Rosner B. . Fundamentals of Biostatistics, Ed. 3 344-456, PWS-Kent Publishing Company Boston 1990.
10. Graff J. R., Konicek B. W., McNulty A. M., Wang Z., Houck K., Allen S., Paul J. D., Hbaiu A., Goode R. G., Sandusky G. E., Vessella R. L., Neubauer B. L. Increased Akt activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27kip1 expression. J. Biol. Chem., 275: 24500-24505, 2000.[Abstract/Free Full Text]
11. Paweletz C. P., Charboneau L., Bichsel V. E., Simone N. L., Chen T., Gillespie J. W., Emmert-Buck M. R., Roth M. J., Petricoin E. F., III, Liotta L. A. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene, 20: 1981-1989, 2001.[CrossRef][Medline]
12. Gioeli D., Mandell J. W., Petroni G. R., Frierson H. F., Weber M. J. Activation of mitogen associated protein kinase associated with prostate cancer progression. Cancer Res., 59: 279-284, 1999.[Abstract/Free Full Text]
13. Zimmerman S., Moelling K. Phosphorylation and regulation of Raf by Akt (Protein kinase B). Science (Wash. DC), 286: 1741-1744, 1999.[Abstract/Free Full Text]

This article has been cited by other articles:

				J. Bodo, L. Durkin, and E. D. Hsi Quantitative In Situ Detection of Phosphoproteins in Fixed Tissues Using Quantum Dot Technology J. Histochem. Cytochem., July 1, 2009; 57(7): 701 - 708. [Abstract] [Full Text] [PDF]

				A. Shukla-Dave, H. Hricak, N. Ishill, C. S. Moskowitz, M. Drobnjak, V. E. Reuter, K. L. Zakian, P. T. Scardino, and C. Cordon-Cardo Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles Clin. Cancer Res., June 1, 2009; 15(11): 3842 - 3849. [Abstract] [Full Text] [PDF]

				A. Shukla-Dave, H. Hricak, N. M. Ishill, C. S. Moskowitz, M. Drobnjak, V. E. Reuter, K. L. Zakian, P. T. Scardino, and C. Cordon-Cardo Correlation of MR Imaging and MR Spectroscopic Imaging Findings with Ki-67, Phospho-Akt, and Androgen Receptor Expression in Prostate Cancer Radiology, March 1, 2009; 250(3): 803 - 812. [Abstract] [Full Text] [PDF]

				R. Kumar, S. Srinivasan, S. Koduru, P. Pahari, J. Rohr, N. Kyprianou, and C. Damodaran Psoralidin, an Herbal Molecule, Inhibits Phosphatidylinositol 3-Kinase-Mediated Akt Signaling in Androgen-Independent Prostate Cancer Cells Cancer Prevention Research, March 1, 2009; 2(3): 234 - 243. [Abstract] [Full Text] [PDF]

				P. A Dennis Targeting Akt in Cancer: Promise, Progress, and Potential Pitfalls Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 25 - 35. [Abstract] [Full Text] [PDF]

				X. Zhang, M.-T. Ling, Q. Wang, C.-K. Lau, S. C. L. Leung, T. K. Lee, A. L. M. Cheung, Y.-C. Wong, and X. Wang Identification of a Novel Inhibitor of Differentiation-1 (ID-1) Binding Partner, Caveolin-1, and Its Role in Epithelial-Mesenchymal Transition and Resistance to Apoptosis in Prostate Cancer Cells J. Biol. Chem., November 16, 2007; 282(46): 33284 - 33294. [Abstract] [Full Text] [PDF]

				C. Festuccia, G. L. Gravina, P. Muzi, R. Pomante, L. Ventura, R. L Vessella, C. Vicentini, and M. Bologna Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer Endocr. Relat. Cancer, September 1, 2007; 14(3): 601 - 611. [Abstract] [Full Text] [PDF]

				J. A. Crowell, V. E. Steele, and J. R. Fay Targeting the AKT protein kinase for cancer chemoprevention Mol. Cancer Ther., August 1, 2007; 6(8): 2139 - 2148. [Abstract] [Full Text] [PDF]

				M. M. Shen and C. Abate-Shen Pten Inactivation and the Emergence of Androgen-Independent Prostate Cancer Cancer Res., July 15, 2007; 67(14): 6535 - 6538. [Abstract] [Full Text] [PDF]

				C. F. MacManus, J. Pettigrew, A. Seaton, C. Wilson, P. J. Maxwell, S. Berlingeri, C. Purcell, M. McGurk, P. G. Johnston, and D. J.J. Waugh Interleukin-8 Signaling Promotes Translational Regulation of Cyclin D in Androgen-Independent Prostate Cancer Cells Mol. Cancer Res., July 1, 2007; 5(7): 737 - 748. [Abstract] [Full Text] [PDF]

				R. Bedolla, T. J. Prihoda, J. I. Kreisberg, S. N. Malik, N. K. Krishnegowda, D. A. Troyer, and P. M. Ghosh Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation Clin. Cancer Res., July 1, 2007; 13(13): 3860 - 3867. [Abstract] [Full Text] [PDF]

				A. P. Kumar, S. Bhaskaran, M. Ganapathy, K. Crosby, M. D. Davis, P. Kochunov, J. Schoolfield, I-T. Yeh, D. A. Troyer, and R. Ghosh Akt/cAMP-Responsive Element Binding Protein/Cyclin D1 Network: A Novel Target for Prostate Cancer Inhibition in Transgenic Adenocarcinoma of Mouse Prostate Model Mediated by Nexrutine, a Phellodendron Amurense Bark Extract Clin. Cancer Res., May 1, 2007; 13(9): 2784 - 2794. [Abstract] [Full Text] [PDF]

				H. Li, X. Wang, N. Li, J. Qiu, Y. Zhang, and X. Cao hPEBP4 Resists TRAIL-induced Apoptosis of Human Prostate Cancer Cells by Activating Akt and Deactivating ERK1/2 Pathways J. Biol. Chem., February 16, 2007; 282(7): 4943 - 4950. [Abstract] [Full Text] [PDF]

				M. G. Fakih, D. L. Trump, J. R. Muindi, J. D. Black, R. J. Bernardi, P. J. Creaven, J. Schwartz, M. G. Brattain, A. Hutson, R. French, et al. A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors Clin. Cancer Res., February 15, 2007; 13(4): 1216 - 1223. [Abstract] [Full Text] [PDF]

				J. Foster, J. Black, C. LeVea, T. Khoury, B. Kuvshinoff, M. Javle, and J. F. Gibbs COX-2 Expression in Hepatocellular Carcinoma is an Initiation Event; While EGF Receptor Expression with Downstream Pathway Activation is a Prognostic Predictor of Survival Ann. Surg. Oncol., February 1, 2007; 14(2): 752 - 758. [Abstract] [Full Text] [PDF]

				H. Gao, X. Ouyang, W. A. Banach-Petrosky, W. L. Gerald, M. M. Shen, and C. Abate-Shen Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer PNAS, September 26, 2006; 103(39): 14477 - 14482. [Abstract] [Full Text] [PDF]

				L. Moro, A. A. Arbini, E. Marra, and M. Greco Up-regulation of Skp2 after Prostate Cancer Cell Adhesion to Basement Membranes Results in BRCA2 Degradation and Cell Proliferation J. Biol. Chem., August 4, 2006; 281(31): 22100 - 22107. [Abstract] [Full Text] [PDF]

				K. S. Chadha, T. Khoury, J. Yu, J. D. Black, J. F. Gibbs, B. W. Kuvshinoff, D. Tan, M. G. Brattain, and M. M. Javle Activated Akt and Erk Expression and Survival After Surgery in Pancreatic Carcinoma Ann. Surg. Oncol., July 1, 2006; 13(7): 933 - 939. [Abstract] [Full Text] [PDF]

				L. A. Gomez, A. de las Pozas, and C. Perez-Stable Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells Mol. Cancer Ther., May 1, 2006; 5(5): 1216 - 1226. [Abstract] [Full Text] [PDF]

				J. Tsurutani, J. Fukuoka, H. Tsurutani, J. H. Shih, S. M. Hewitt, W. D. Travis, J. Jen, and P. A. Dennis Evaluation of Two Phosphorylation Sites Improves the Prognostic Significance of Akt Activation in Non-Small-Cell Lung Cancer Tumors J. Clin. Oncol., January 10, 2006; 24(2): 306 - 314. [Abstract] [Full Text] [PDF]

				J Lim, J-H Kim, J-Y Paeng, M-J Kim, S-D Hong, J-I Lee, and S-P Hong Prognostic value of activated Akt expression in oral squamous cell carcinoma J. Clin. Pathol., November 1, 2005; 58(11): 1199 - 1205. [Abstract] [Full Text] [PDF]

				L. Yang, S. Xie, Md. S. Jamaluddin, S. Altuwaijri, J. Ni, E. Kim, Y.-T. Chen, Y.-C. Hu, L. Wang, K.-H. Chuang, et al. Induction of Androgen Receptor Expression by Phosphatidylinositol 3-Kinase/Akt Downstream Substrate, FOXO3a, and Their Roles in Apoptosis of LNCaP Prostate Cancer Cells J. Biol. Chem., September 30, 2005; 280(39): 33558 - 33565. [Abstract] [Full Text] [PDF]

				E. Galanis, J. C. Buckner, M. J. Maurer, J. I. Kreisberg, K. Ballman, J. Boni, J. M. Peralba, R. B. Jenkins, S. R. Dakhil, R. F. Morton, et al. Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study J. Clin. Oncol., August 10, 2005; 23(23): 5294 - 5304. [Abstract] [Full Text] [PDF]

				M. Fassnacht, D. Weismann, S. Ebert, P. Adam, M. Zink, F. Beuschlein, S. Hahner, and B. Allolio AKT Is Highly Phosphorylated in Pheochromocytomas But Not in Benign Adrenocortical Tumors J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4366 - 4370. [Abstract] [Full Text] [PDF]

				X. Yang, M.-W. Chen, S. Terry, F. Vacherot, D. K. Chopin, D. L. Bemis, J. Kitajewski, M. C. Benson, Y. Guo, and R. Buttyan A Human- and Male-Specific Protocadherin that Acts through the Wnt Signaling Pathway to Induce Neuroendocrine Transdifferentiation of Prostate Cancer Cells Cancer Res., June 15, 2005; 65(12): 5263 - 5271. [Abstract] [Full Text] [PDF]

				L. Moro, A. A. Arbini, E. Marra, and M. Greco Down-regulation of BRCA2 Expression by Collagen Type I Promotes Prostate Cancer Cell Proliferation J. Biol. Chem., June 10, 2005; 280(23): 22482 - 22491. [Abstract] [Full Text] [PDF]

				A. Shah, W. A. Swain, D. Richardson, J. Edwards, D. J. Stewart, C. M. Richardson, D. E.B. Swinson, D. Patel, J. L. Jones, and K. J. O'Byrne Phospho-Akt Expression Is Associated with a Favorable Outcome in Non-Small Cell Lung Cancer Clin. Cancer Res., April 15, 2005; 11(8): 2930 - 2936. [Abstract] [Full Text] [PDF]

				P. M Ghosh, S. N Malik, R. G Bedolla, Y. Wang, M. Mikhailova, T. J Prihoda, D. A Troyer, and J. I Kreisberg Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation Endocr. Relat. Cancer, March 1, 2005; 12(1): 119 - 134. [Abstract] [Full Text] [PDF]

				R. L. Lynch, B. W. Konicek, A. M. McNulty, K. R. Hanna, J. E. Lewis, B. L. Neubauer, and J. R. Graff The Progression of LNCaP Human Prostate Cancer Cells to Androgen Independence Involves Decreased FOXO3a Expression and Reduced p27KIP1 Promoter Transactivation Mol. Cancer Res., March 1, 2005; 3(3): 163 - 169. [Abstract] [Full Text] [PDF]

				D. DeFeo-Jones, S. F. Barnett, S. Fu, P. J. Hancock, K. M. Haskell, K. R. Leander, E. McAvoy, R. G. Robinson, M. E. Duggan, C. W. Lindsley, et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members Mol. Cancer Ther., February 1, 2005; 4(2): 271 - 279. [Abstract] [Full Text] [PDF]

				G. V. Thomas, S. Horvath, B. L. Smith, K. Crosby, L. A. Lebel, M. Schrage, J. Said, J. De Kernion, R. E. Reiter, and C. L. Sawyers Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8351 - 8356. [Abstract] [Full Text] [PDF]

				S. Bandyopadhyay, S. K. Pai, S. Hirota, S. Hosobe, T. Tsukada, K. Miura, Y. Takano, K. Saito, T. Commes, D. Piquemal, et al. PTEN Up-Regulates the Tumor Metastasis Suppressor Gene Drg-1 in Prostate and Breast Cancer Cancer Res., November 1, 2004; 64(21): 7655 - 7660. [Abstract] [Full Text] [PDF]

				V. J. Assikis, K.-A. Do, S. Wen, X. Wang, J. H. Cho-Vega, S. Brisbay, R. Lopez, C. J. Logothetis, P. Troncoso, C. N. Papandreou, et al. Clinical and Biomarker Correlates of Androgen-Independent, Locally Aggressive Prostate Cancer with Limited Metastatic Potential Clin. Cancer Res., October 15, 2004; 10(20): 6770 - 6778. [Abstract] [Full Text] [PDF]

				O. David, J. Jett, H. LeBeau, G. Dy, J. Hughes, M. Friedman, and A. R. Brody Phospho-Akt Overexpression in Non-Small Cell Lung Cancer Confers Significant Stage-Independent Survival Disadvantage Clin. Cancer Res., October 15, 2004; 10(20): 6865 - 6871. [Abstract] [Full Text] [PDF]

				D. F. Stern More than a Marker... Phosphorylated Akt in Prostate Carcinoma Clin. Cancer Res., October 1, 2004; 10(19): 6407 - 6410. [Full Text] [PDF]

				G. Ayala, T. Thompson, G. Yang, A. Frolov, R. Li, P. Scardino, M. Ohori, T. Wheeler, and W. Harper High Levels of Phosphorylated Form of Akt-1 in Prostate Cancer and Non-Neoplastic Prostate Tissues Are Strong Predictors of Biochemical Recurrence Clin. Cancer Res., October 1, 2004; 10(19): 6572 - 6578. [Abstract] [Full Text] [PDF]

				A. R. Uzgare and J. T. Isaacs Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells Cancer Res., September 1, 2004; 64(17): 6190 - 6199. [Abstract] [Full Text] [PDF]

				J. I. Kreisberg, S. N. Malik, T. J. Prihoda, R. G. Bedolla, D. A. Troyer, S. Kreisberg, and P. M. Ghosh Phosphorylation of Akt (Ser473) is an Excellent Predictor of Poor Clinical Outcome in Prostate Cancer Cancer Res., August 1, 2004; 64(15): 5232 - 5236. [Abstract] [Full Text] [PDF]

				T. R. Salas, J. Kim, F. Vakar-Lopez, A. L. Sabichi, P. Troncoso, G. Jenster, A. Kikuchi, S.-Y. Chen, L. Shemshedini, M. Suraokar, et al. Glycogen Synthase Kinase-3{beta} Is Involved in the Phosphorylation and Suppression of Androgen Receptor Activity J. Biol. Chem., April 30, 2004; 279(18): 19191 - 19200. [Abstract] [Full Text] [PDF]

				K. Jorgensen, R. Holm, G. M. Maelandsmo, and V. A. Florenes Expression of Activated Extracellular Signal-Regulated Kinases 1/2 in Malignant Melanomas: Relationship with Clinical Outcome Clin. Cancer Res., November 1, 2003; 9(14): 5325 - 5331. [Abstract] [Full Text] [PDF]

				Y. Tanaka, M. V. Gavrielides, Y. Mitsuuchi, T. Fujii, and M. G. Kazanietz Protein Kinase C Promotes Apoptosis in LNCaP Prostate Cancer Cells through Activation of p38 MAPK and Inhibition of the Akt Survival Pathway J. Biol. Chem., September 5, 2003; 278(36): 33753 - 33762. [Abstract] [Full Text] [PDF]

				A. Handra-Luca, H. Bilal, J.-C. Bertrand, and P. Fouret Extra-Cellular Signal-Regulated ERK-1/ERK-2 Pathway Activation in Human Salivary Gland Mucoepidermoid Carcinoma: Association to Aggressive Tumor Behavior and Tumor Cell Proliferation Am. J. Pathol., September 1, 2003; 163(3): 957 - 967. [Abstract] [Full Text] [PDF]

				V. Grunwald and M. Hidalgo Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment J Natl Cancer Inst, June 18, 2003; 95(12): 851 - 867. [Abstract] [Full Text] [PDF]

				I. K. Mellinghoff, C. Tran, and C. L. Sawyers Growth Inhibitory Effects of the Dual ErbB1/ErbB2 Tyrosine Kinase Inhibitor PKI-166 on Human Prostate Cancer Xenografts Cancer Res., September 15, 2002; 62(18): 5254 - 5259. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Malik, S. N. Articles by Kreisberg, J. I. Search for Related Content PubMed PubMed Citation Articles by Malik, S. N. Articles by Kreisberg, J. I.